AbbVie and BioMed X collaborate to develop novel approaches for the treatment of Alzheimer’s Disease
Heidelberg, Germany, March 30, 2015 – AbbVie and BioMed X announced today that they have entered into a collaboration agreement to establish a research group focusing on new treatment options of tau pathology in Alzheimer’s Disease (AD).
As part of BioMed X’s new innovation model, outstanding early career scientists from leading academic institutions world-wide are invited to submit original project proposals focusing on intracellular tau processing and clearance, including proteostasis, as well as studies to elucidate how tau processing is affected by AD-related alterations such as elevated oligomeric amyloid-beta, or the genetic factors linked to late onset AD.
AbbVie and BioMed X will jointly select the best ideas and research talents to form a new research group within BioMed X’s open innovation lab on the multi-disciplinary life science campus of the University of Heidelberg. The unique supportive setting of BioMed X and AbbVie provides an exciting opportunity for the selected young researchers to combine state-of-the-art academic research with AbbVie’s drug development know-how in order to elaborate completely new treatment options.
“The need for new treatment options of tau pathology in Alzheimer’s Disease is critical. This collaboration agreement addresses this need and combines the best of the academic and industry worlds”, said Alfred Hahn, Senior Director and Head of Discovery at AbbVie. “We are very excited about our collaboration with AbbVie since it is the first US-based pharma company that supports our new innovation model”, said Christian Tidona, founder and Managing Director of BioMed X.
Further details of the agreement and financial terms are not disclosed.
About BioMed X Innovation Center
The BioMed X Innovation Center is an exciting new collaboration model at the interface between academia and industry. At our center, distinguished early career scientists recruited from all over the world are working jointly on novel pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, diagnostics and bioinformatics. These interdisciplinary project teams are conducting groundbreaking biomedical research in an open innovation lab facility on the campus of the University of Heidelberg, under the guidance of experienced mentors from academia and industry while expanding their scientific network and receiving an intensive entrepreneurship and leadership training. Each team is typically sponsored by a corporate pharma or biotech partner of BioMed X. After a fully funded project term, successful projects are either internalized into the development pipeline of the respective pharma or biotech sponsor or spun off into an independent startup company.
For more information please visit www.bio.mx.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs more than 26,000 people worldwide and markets medicines in more than 170 countries.